STOCK TITAN

Freeline to Participate in Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Freeline Therapeutics Holdings plc (Nasdaq: FRLN) will be participating in two upcoming investor conferences in August. CEO Michael Parini will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on August 7. The management will also participate in one-on-one meetings at the Wedbush Healthcare Conference from August 8-9 in New York City. A live webcast of the BTIG fireside chat will be available on Freeline's website.
Positive
  • None.
Negative
  • None.

LONDON, July 31, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that the company will be participating in two upcoming investor conferences in August. Details are as follows:

BTIG Virtual Biotechnology Conference

Freeline Chief Executive Officer Michael Parini will participate in a fireside chat at 10 a.m. ET on Monday, August 7. Management will also participate in one-on-one meetings as part of the virtual conference.

Wedbush Healthcare Conference

Management will participate in one-on-one investor meetings at the conference, which is taking place from August 8-9 at the Lotte Palace Hotel in New York City.

A live webcast of the BTIG fireside chat will be available on the Investors section of Freeline’s website at www.freeline.life. An archived replay of the webcast will be available for approximately 90 days following the presentation.

About Freeline Therapeutics
Freeline is a clinical-stage biotechnology company focused on developing transformative gene therapies for chronic debilitating diseases. Freeline uses its proprietary, rationally designed AAV vector and capsid (AAVS3), along with novel promoters and transgenes, to deliver a functional copy of a therapeutic gene into human liver cells, thereby expressing a persistent functional level of the missing or dysfunctional protein into a patient’s bloodstream. The company is currently advancing FLT201, a highly differentiated gene therapy candidate that delivers a novel transgene, in a Phase 1/2 clinical trial in people with Gaucher disease type 1. Freeline has additional programs in research, including one focused on GBA1-linked Parkinson’s disease that leverages the same novel transgene as FLT201. Freeline is headquartered in the UK and has operations in the United States. For more information, visit www.freeline.life or connect with Freeline on LinkedIn and Twitter.

Media and Investor Contact:
Naomi Aoki
naomi.aoki@freeline.life
Senior Vice President, Head of Investor Relations & Communications
+ 1 617 283 4298


FAQ

What is the company participating in?

Freeline Therapeutics Holdings plc is participating in two upcoming investor conferences in August.

Who will participate in the fireside chat at the BTIG Virtual Biotechnology Conference?

CEO Michael Parini will participate in the fireside chat at the BTIG Virtual Biotechnology Conference.

Where will the Wedbush Healthcare Conference take place?

The Wedbush Healthcare Conference will take place at the Lotte Palace Hotel in New York City.

Where can I watch the live webcast of the BTIG fireside chat?

The live webcast of the BTIG fireside chat will be available on Freeline's website.

How long will the archived replay of the webcast be available?

The archived replay of the webcast will be available for approximately 90 days following the presentation.

Freeline Therapeutics Holdings plc

NASDAQ:FRLN

FRLN Rankings

FRLN Latest News

FRLN Stock Data

28.24M
26.80M
1.1%
45.88%
0.55%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United Kingdom
Stevenage

About FRLN

freeline is a biopharmaceutical company focused on the development and commercialisation of gene therapies for bleeding and other debilitating disorders based on a next-generation aav gene therapy platform developed by amit nathwani, professor of haematology at ucl and cso of freeline therapeutics http://www.freelinetx.com